Related frontier molecules
NAD+, metformin, rapamycin, and other frontier molecules belong in the conversation, but not in the peptide category. Browse their regulatory status, human evidence, risks, and unknowns here.
Showing 13 of 13 molecule fact sheets
Related science, clearly separated from peptides
Cellular coenzyme
A central cellular coenzyme with legitimate biology but little clinical-outcomes evidence for wellness infusions.
Vitamin B3-related NAD+ precursor
An NAD+ precursor that reliably changes biomarkers but has not shown a consistent anti-aging or cognitive benefit.
NAD+ precursor
An NAD+ precursor with small human trials and unresolved real-world clinical value.
mTOR-inhibiting medicine
An FDA-approved immunosuppressant with serious risks and unproven longevity use in healthy people.
Biguanide medicine
A foundational diabetes medicine being studied in geroscience, without an approved anti-aging use.
Gut-microbiome-derived metabolite
A mitophagy-related metabolite with human biomarker and muscle-endurance signals but no approved disease use.
Naturally occurring polyamine
A food-derived polyamine linked to autophagy biology, with a negative phase 2 cognitive primary outcome.
Flavonoid and experimental senolytic
A plant flavonoid with striking mouse senolytic findings but no proven human longevity or frailty benefit.
Investigational senolytic drug combination
An experimental senolytic pairing that combines a serious cancer medicine with a flavonoid.
Energy-cycle metabolite
A central metabolic intermediate with mouse healthspan findings and unfinished human geroscience questions.
Amino sulfonic acid
A common nutrient-related molecule whose animal longevity story is challenged by human aging data.
Cellular energy-buffering compound
A well-studied performance supplement with credible muscle evidence and a less certain cognitive-aging frontier.
Ketone metabolite and precursor formulations
Compounds that raise circulating ketones reliably but have not established cognitive or healthy-aging benefit.